The Invisible Epidemic: Smokeless Tobacco in South Asia

In the nicotine policy debates that dominate Western public health discourse, an entire category of products is systematically invisible. Smokeless tobacco—chewing tobacco, snuff, gutka, paan masala, khaini, and dozens of other regional variants—is used by an estimated 300 million people in South Asia alone, roughly a quarter of the world's total nicotine users. It causes oral cancer at rates that are among the highest in the world, with India accounting for nearly a third of global oral cancer cases. It's produced by a vast informal industry, sold at millions of small retail outlets, and consumed across all socioeconomic strata—from rural farmers to urban professionals. And it exists in a regulatory near-vacuum: minimally taxed, inconsistently regulated, and largely ignored by the FCTC implementation frameworks that were designed for combustible cigarettes. The smokeless tobacco epidemic in South Asia is a case study in how global tobacco control has systematically neglected the products that affect the world's poorest populations.

The product landscape of South Asian smokeless tobacco is bewilderingly diverse and deeply embedded in cultural practice. Gutka is a mixture of crushed areca nut, tobacco, lime, and flavorings, sold in small foil packets for pennies. Paan masala combines areca nut with lime and spices, often with tobacco added. Khaini is a mixture of tobacco and lime, held in the mouth. These products are not imported Western innovations. They're indigenous traditions that predate the arrival of commercial cigarettes by centuries and that have been transformed—through industrialization, commercialization, and aggressive marketing—into a public health catastrophe. The cultural embeddedness of these products makes them harder to regulate than cigarettes, which lack the same cultural legitimacy. A ban on gutka, implemented in many Indian states, is systematically circumvented because the product can be assembled from separately sold components. The regulatory challenge is not just weak enforcement. It's the nature of the products themselves.

The health burden of South Asian smokeless tobacco is staggering and concentrated in the most visible and disfiguring form of tobacco-related disease: oral cancer. India has the highest rate of oral cancer in the world, with over 100,000 new cases annually, overwhelmingly associated with smokeless tobacco use. The cancers are aggressive, often diagnosed late, and treated with surgeries that remove parts of the jaw, tongue, and face—leaving survivors with profound disability and social stigma. The economic burden falls disproportionately on poor families, who may spend their life savings on cancer treatment and lose their primary earner to disease or death. The oral cancer epidemic in South Asia is one of the most severe and least-recognized public health crises in the world. It receives a fraction of the global attention given to lung cancer, because it affects poor people in poor countries using products that Western researchers and policymakers have never heard of.

The regulatory neglect of smokeless tobacco reflects a broader pattern in global health governance. The WHO FCTC applies to 'all tobacco products' in principle, but its provisions were designed for combustible cigarettes and are poorly adapted to smokeless products. Advertising restrictions designed for billboards and magazines don't address the point-of-sale marketing and informal distribution networks that characterize the smokeless tobacco market. Tax structures designed for factory-manufactured cigarettes don't capture the informal production of gutka and paan masala. Health warning requirements designed for cigarette packs don't translate to the small foil sachets in which smokeless tobacco is typically sold. The result is a global tobacco control framework that nominally covers all tobacco products but functionally regulates only the ones that Western policymakers understand. The smokeless tobacco user in rural Bihar is invisible to the international institutions that are supposed to protect them.

The harm-reduction dimension of smokeless tobacco is complex and under-explored. In the Western nicotine debate, 'smokeless' has come to mean Swedish snus and American nicotine pouches—products with dramatically reduced toxicant profiles compared to South Asian smokeless tobacco. The carcinogenicity of South Asian smokeless products is high (due to tobacco-specific nitrosamines formed during the curing process, the addition of lime that damages oral mucosa and enhances carcinogen absorption, and the areca nut that's itself a Group 1 carcinogen). Western harm-reduction products (snus, pouches) have minimal cancer risk. Applying the 'smokeless = safer' framing from Western harm reduction to South Asian smokeless products would be dangerously misleading. The harm-reduction approach in South Asia must be specific to the products and the context: encouraging a transition from high-nitrosamine indigenous products to lower-nitrosamine alternatives, while recognizing that complete tobacco cessation remains the safest outcome.

The regulatory response to smokeless tobacco in South Asia has been inconsistent and largely ineffective. India's state-level gutka bans, implemented under food safety regulations (gutka is classified as a food product in some jurisdictions), have been partially effective but undermined by the availability of twin-pack products (tobacco and areca nut mixtures sold as separate components that the consumer combines). Taxation is minimal and poorly enforced. Cessation services for smokeless tobacco users are virtually nonexistent—the smoking-cessation infrastructure that exists in many countries has no equivalent for chewing-tobacco cessation. The policy gap is not a lack of knowledge—the health effects are well-established—but a lack of political will and institutional capacity. The smokeless tobacco industry in South Asia, while less concentrated than the global cigarette industry, is politically influential, economically significant (employing millions), and culturally embedded. Regulating it requires confronting interests that are more diffuse but no less powerful than the multinational cigarette companies.

The South Asian smokeless tobacco epidemic is a reminder that the global nicotine problem is far larger and more diverse than the Western policy debate acknowledges. Addressing it requires expanding the scope of tobacco control beyond the products that dominate Western discourse—cigarettes, e-cigarettes, nicotine pouches—to include the products that affect hundreds of millions of people who are invisible to Western researchers and policymakers. It requires developing regulatory frameworks that are adapted to informal markets, diverse product categories, and deep cultural embeddedness. It requires investing in the research infrastructure to understand the toxicology, epidemiology, and behavioral economics of products that have been systematically understudied. And it requires acknowledging that the global tobacco control movement, for all its achievements, has not adequately served the populations—overwhelmingly poor, overwhelmingly in LMICs—who use the products that the movement has most neglected.